JK1033
/ Tianjin Jikun Pharmaceutical Technology
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
August 07, 2025
A Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Doses, Food Effect Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral JK1033 Administration in Healthy Volunteers
(ChiCTR)
- P1 | N=70 | Not yet recruiting | Sponsor: Peking University Third Hospital; Jikun PharmSci & Tech (Tianjin) Co. Ltd.
New P1 trial • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 1
Of
1
Go to page
1